Why Pharvaris N.V.’s (PHVS) Stock Is Up 5.07%
As of Tuesday, October 20, Pharvaris N.V.’s PHVS share price has surged by 5.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Commentary & Analysis
Why Pharvaris N.V.’s (PHVS) Stock Is Up 7.64%
As of Friday, September 11, Pharvaris N.V.’s PHVS share price has surged by 7.64%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Pharvaris N.V.’s (PHVS) Stock Is Up 15.46%
As of Tuesday, September 08, Pharvaris N.V.’s PHVS share price has surged by 15.46%, which has investors questioning if this is right time to sell.Michael Rose
Why Pharvaris N.V.’s (PHVS) Stock Is Up 5.21%
As of Thursday, June 25, Pharvaris N.V.’s PHVS share price has surged by 5.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Pharvaris N.V.’s (PHVS) Stock Is Up 6.36%
As of Wednesday, June 17, Pharvaris N.V.’s PHVS share price has surged by 6.36%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,153.9 | $500.9 | 56% |
|
| Shares Out (Mil) | 77.8 | 42.7 | 57% |
|
| Institutional Ownership | 96.8% | 81.3% | 71% |
|
| Float (Mil) | 44.1 | 45.6 | 44% |
|
| Beta | -2.33 | 0.73 | 0% |
|
| Avg Daily Volume (000s) | 706 | 303 | 64% |
|
| Price Change (52-week) |
27.9% | 56.3% | 75% |
|
| Growth | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (45.3%) | (2.4%) | 8% |
|
| EPS (5yr) | 11.9% | 14.9% | 51 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (58.9%) | (15.1%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 13 | 12 | |
| Current EPS | ($0.806) | ($3.107) | ($3.049) | |
| Month Ago EPS | ($0.803) | ($3.098) | ($3.037) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.751) | ($2.964) | ($2.733) | |
| Year/Year Chg | 0.4% | (10.9%) | (71.3%) | |
| Financials | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($195) | ($11) | 7% |
|
| EPS (TTM) | ($2.994) | ($0.700) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($177) | ($7) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $146 | $6 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 15% |
|
| Enterprise Value (Q1) (Mil) | $2,171 | $493 | 50% |
|
| Valuation | PHVS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.26 | 2.09 | 84% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (60.7%) | (22.2%) | 10% |
|
| ROE | (66.5%) | (21.0%) | 13% |
|
| Liabilities to Assets | 8.5% | 32.3% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
Pharvaris N.V. did not pass any screens on 10/22/2026.
